Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Cognigenics' Intranasal CRISPR Delivery Bypasses Blood-Brain Barrier; Potential Breakthrough Therapeutic

Cognigenics CEO John L. Mee announces breakthrough results from an animal study published today in PNAS Nexus. The findings point to the potential of non-invasively delivering neuromodulating gene therapies to the brain for chronic mental health conditions using adeno-associated viruses introduced intranasally.

"Our patent-pending CRISPR/Cas9 delivery system enabled us to bypass the blood-brain barrier by intranasally administering therapeutics to reach the central nervous system via the neural pathways in the nasal cavity," said Director of Preclinical Studies Troy Rohn, PhD, principal investigator of the study. "In the study, a single dose significantly reduced anxiety in mice, demonstrating that complex behavioral traits can be directly modified by this non-invasive technique."

Chief Medical Officer Barry J. Linder, MD added, "While our findings are preliminary, they may lead to a new class of long-lasting therapeutics with fewer side effects than SSRIs for mental health conditions including anxiety, depression and ADHD, as well as for some genetic conditions."

Significant reduction in anxiety

The animal study tested a platform of CRISPR/Cas9 utilizing two adeno-associated viruses (AAVs) to deliver anti-anxiety reagents in vivo to the part of the brain that is overactive in anxiety. The method requires two delivery vectors because of the limited cargo capacity of the viruses. Each virus was modified using Cognigenics' proprietary CRISPR gene-editing technology.

Treated mice showed 35.7% and 14.8% decreases in two standard measures of anxiety.

No toxicity or neurologic damage

Importantly, there was no evidence of toxicity at any concentration following treatment, and neurons were healthy.

About CRISPR technology

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary genetic technology that allows precise editing of DNA. It functions like molecular scissors, cutting DNA at a specific location and allowing researchers to add, remove, or replace specific sections of genetic code. CRISPR has the potential for treating a wide range of genetic diseases and mental health conditions.

About Cognigenics

Founded in 2019, Cognigenics works at the forefront of genetic neuroengineering through patent-pending CRISPR technology to precisely and noninvasively target and modulate the underlying neural circuits responsible for mental health disorders such as anxiety, depression, ADHD, and some forms of cognitive impairment.

Learn more at www.cognigenics.io.

These press releases may also interest you

at 03:21
While traditional cultural art forms presumably tend to struggle in resonating with younger generations, China's latest Yueju Opera production, New Dragon Gate Inn performed by Xiao Bai Hua, one of the most remarkable Yueju Opera troupes from East...

at 03:15
Technavio categorizes the global automotive lighting market as a part of the global automotive components and accessories market. The global automotive lighting market is fragmented, with the presence of several global as well as regional vendors. A...

at 03:15
Recently, Morgan Stanley Capital International (MSCI), an authoritative international index agency, announced the results of its latest ESG (Environmental, Social and Governance) ratings, and 37 Interactive Entertainment's rating jumped to AA, making...

at 03:10
In a significant move for digital transformation, Mastercard has selected KOBIL GmbH, a leading technology company based in Germany, as its partner for future digital ecosystem-based projects. This collaboration aims to foster innovative business...

at 03:07
Global consulting firm J.S. Held announces the expansion of the Digital Investigations & Discovery team in Europe and the Asia Pacific with the addition of four experts ? Chantelle Jalland, Benjamin Guinard, Marybeth Kings, and Mayank Sharma, who...

at 03:05
Syngenta Crop Protection, a global leader in agricultural innovation, has become a sponsor of the International Alliance for Phytobiomes Research, cementing a partnership between the research community and industry that is aimed at advancing both...

News published on and distributed by: